You are here

JPMHC 2018

Three Interviews From the J.P. Morgan Healthcare Conference

Three Interviews From the J.P. Morgan Healthcare Conference

Motley Fool

Arena Pharmaceuticals

Spark Therapeutics

Flag link:

Closing JPM18: Winners and losers, brighter days for neuroscience

Closing JPM18: Winners and losers, brighter days for neuroscience

Biopharma Dive

channel stuffing

Flag link:

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

Changes to Federal Tax Law Just What the Doctor Ordered for Healthcare Firms

TheStreet.com

Flag link:

JPM18: Novavax investors cheer RSV vaccine update, then pull back

JPM18: Novavax investors cheer RSV vaccine update, then pull back

Biopharma Dive

Flag link:

Here's What Celgene's Management Just Said About Its Future

Here's What Celgene's Management Just Said About Its Future

Motley Fool

Flag link:

J&J chief’s pharma-tech vision is pretty, but it’s certainly not reality: experts

J&J chief’s pharma-tech vision is pretty, but it’s certainly not reality: experts

Fierce Pharma

Flag link:

After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO

After 5 years, Eliquis' growth ceiling is nowhere in sight: Bristol-Myers CEO

Fierce Pharma

Bristol-Myers Squibb

Giovanni Caforio

Flag link:

Biotech CEOs unfazed by Brexit

Biotech CEOs unfazed by Brexit

Biopharma Dive

Flag link:

Lilly CEO: With pharma friends in high places, it's 'time for action' to ease drug costs

Lilly CEO: With pharma friends in high places, it's 'time for action' to ease drug costs

Fierce Pharma

Flag link:

JPM18: Incyte and Syros to collaborate in cancer R&D

JPM18: Incyte and Syros to collaborate in cancer R&D

Biopharma Dive

Syros Pharmaceuticals

Flag link:

JPM18: GSK's Walmsley weighs in on Pfizer, gender diversity

JPM18: GSK's Walmsley weighs in on Pfizer, gender diversity

Biopharma Dive

gender diversity

Flag link:

JPM18: bluebird set to file 3 drugs for approval by 2019

JPM18: bluebird set to file 3 drugs for approval by 2019

Biopharma Dive

Flag link:

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Sanofi and Regeneron's Dupixent launch is about to get a cash infusion

Fierce Pharma

Flag link:

Drug pricing pressure isn't likely to get worse: Merck CEO

Drug pricing pressure isn't likely to get worse: Merck CEO

Fierce Pharma

Kenneth Frazier

Flag link:

JPMing while female: Women share their experiences at biopharma’s big gathering

JPMing while female: Women share their experiences at biopharma’s big gathering

Stat

women executives

sexual harassment

gender discrimination

Flag link:

5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce

5 Reasons Illumina Enjoyed a Big J.P. Morgan Conference Bounce

Motley Fool

gene sequencing

Flag link:

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Don't expect Restasis generics till at least next quarter, Allergan CEO says

Fierce Pharma

Flag link:

The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past

The 1 Word That Explains Why Pfizer's Future Looks Brighter Than Its Past

Motley Fool

Flag link:

Johnson & Johnson Wants to Create a Crisis -- and That's Great for Investors

Johnson & Johnson Wants to Create a Crisis -- and That's Great for Investors

Motley Fool

Flag link:

The Winners And Losers Of JP Morgan Monday

The Winners And Losers Of JP Morgan Monday

Forbes

Cellular Biomedicine

Alder Biopharmaceuticals

PTC Therapeutics

Axovant Sciences

Oxford Immunotec

Flag link:

Pages